483
Intercept PharmaceuticalsIntercept Pharmaceuticals – FDA 483, Feb 1, 2016
Record Details
An FDA inspection of Intercept Pharmaceuticals, Inc. in San Diego revealed significant deficiencies in clinical trial oversight. The firm failed to adequately monitor studies, retain essential records, and properly document the transfer of obligations to a contract research organization. These issues indicate a lack of robust controls over clinical trial conduct and data integrity.
View Company Profile
ID · 6170efbf-60f4-45a9-b373-63be5382379f
Other documents for Intercept Pharmaceuticals
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.